Lipid Nano-Sphere(LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration. IV

1994 ◽  
Vol 28 (1-3) ◽  
pp. 352-353 ◽  
Author(s):  
J. Seki ◽  
H. Sasaki ◽  
M. Doi ◽  
H. Yoshikawa ◽  
Y. Takahashi ◽  
...  
Keyword(s):  
Drug Carrier ◽  
Parenteral Administration ◽  
Novel Drug

Anti-VEGFR2 Antibody-modified Micelle for Triggered Drug Delivery and Effective Therapy of Choroidal Neovascularization

2019 ◽  
Vol 16 (3) ◽  
pp. 258-265
Author(s):  
Kei Takahashi ◽  
Tomomi Masuda ◽  
Mitsunori Harada ◽  
Tadashi Inoue ◽  
Shinsuke Nakamura ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Choroidal Neovascularization ◽  
Pigment Epithelium ◽  
Drug Carrier ◽  
Retinal Pigment ◽  
Laser Coagulation ◽  
Antiangiogenic Agents ◽  
Drug Carrier System ◽  
Novel Drug ◽  
Drug Delivery Devices

Objective: This study aimed to examine whether DC101 (anti-VEGFR2 antibody)- modified micelles have applications as novel drug delivery devices, which allow small molecule antiangiogenic agents to deliver to angiogenic sites on a murine laser-induced choroidal neovascularization (CNV) model. Materials and Method: CNV was induced by photocoagulation on the unilateral eye of each mouse under anesthesia. Immediately after laser coagulation, E7974-loaded DC101-modified micelles and motesanib-loaded DC101-modified micelles were intravitreally administrated. Two weeks after photocoagulation, CNV was visualized using fluorescein-conjugated dextran (MW=2,000 kDa), and the CNV area was measured in retinal pigment epithelium (RPE)-choroidal flat mounts. Results: Intravitreal administration of both DC101-modified micelles loaded with E7974 at 2 µM and motesanib at 2 µM significantly reduced CNV area in the murine laser-induced CNV model at a clearly lower concentration than the effective dose of each agent. Conclusion: These results suggest that DC101-modified micelle might be effective drug carrier system for treating CNV and other ocular angiogenic diseases.

Chitosan Polymer as Novel Drug Carrier

2015 ◽  
pp. 533-556
Author(s):  
Aakanchha Jain ◽  
Sourabh Jain ◽  
Vikas Jain ◽  
Dharmveer Kohli
Keyword(s):  
Drug Carrier ◽  
Novel Drug

scholarly journals Novel Drug Carrier: 5-Fluorouracil Formulation in Nanoporous Biogenic Mg-calcite from Blue Crab Shells—Proof of Concept

ACS Omega ◽  
2021 ◽  
Author(s):  
Geza Lazar ◽  
Fran Nekvapil ◽  
Razvan Hirian ◽  
Branko Glamuzina ◽  
Tudor Tamas ◽  
...  
Keyword(s):  
Blue Crab ◽  
Drug Carrier ◽  
Proof Of Concept ◽  
Novel Drug

scholarly journals The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System

2015 ◽  
Vol 2015 ◽  
pp. 1-27 ◽  
Author(s):  
Karolina Werengowska-Ciećwierz ◽  
Marek Wiśniewski ◽  
Artur P. Terzyk ◽  
Sylwester Furmaniak
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Polymeric Nanoparticles ◽  
Physical Adsorption ◽  
Drug Carrier ◽  
Anticancer Therapy ◽  
Modern Drug ◽  
Polycyclic Groups ◽  
Novel Drug ◽  
Small Elements

Nanomedicine is, generally, the application of nanotechnology to medicine. The term nanomedicine includes monitoring, construction of novel drug delivery systems, and any possible future applications of nanotechnology and nanovaccinology. In this review, the most important ligand-nanocarrier and drug-nanocarrier bioconjugations are described. The detailed characterizations of covalently formed bonds between targeted ligand and nanocarrier, including amide, thioether, disulfide, acetyl-hydrazone and polycyclic groups, are described. Also, the coupling of small elements and heteroatoms in the form of R-X-R the “click chemistry” groups is shown. Physical adsorption and chemical bonding of drug to nanocarrier surface involving drug on the internal or external surfaces of nanocarriers are described throughout possibility of the formation of the above-mentioned functionalities. Moreover, the most popular nanostructures (liposomes, micelles, polymeric nanoparticles, dendrimers, carbon nanotubes, and nanohorns) are characterized as nanocarriers. Building of modern drug carrier is a new method which could be effectively applied in targeted anticancer therapy.

PEG–poly(amino acid)s-encapsulated tanshinone IIA as potential therapeutics for the treatment of hepatoma

2014 ◽  
Vol 2 (20) ◽  
pp. 3115-3122 ◽  
Author(s):  
Yan Wang ◽  
Frankie Costanza ◽  
Haifan Wu ◽  
Daqian Song ◽  
Jianfeng Cai ◽  
...  
Keyword(s):  
Amino Acid ◽  
Drug Carrier ◽  
Tanshinone Iia ◽  
Novel Drug ◽  
Potential Therapeutics

PEG–poly(amino acid)s are used as a novel drug carrier for the treatment of hepatoma.

Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability

2013 ◽  
Vol 452 (1-2) ◽  
pp. 382-389 ◽  
Author(s):  
Xia Niu ◽  
Long Wan ◽  
Zhong Hou ◽  
Tianyi Wang ◽  
Changshan Sun ◽  
...  
Keyword(s):  
Oral Bioavailability ◽  
Mesoporous Carbon ◽  
Drug Carrier ◽  
Novel Drug

scholarly journals Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions

2022 ◽  
Vol 23 (2) ◽  
pp. 836
Author(s):  
Melissa Jones ◽  
Corina Mihaela Ionescu ◽  
Daniel Walker ◽  
Susbin Raj Wagle ◽  
Bozica Kovacevic ◽  
...  
Keyword(s):  
Oral Delivery ◽  
Drug Carrier ◽  
Pharmaceutical Formulations ◽  
Oral Route ◽  
Chronic Medical Conditions ◽  
Potential Applications ◽  
Novel Drug ◽  
Carrier Systems ◽  
Drug Carrier Systems

Biguanides, particularly the widely prescribed drug metformin, have been marketed for many decades and have well-established absorption profiles. They are commonly administered via the oral route and, despite variation in oral uptake, remain commonly prescribed for diabetes mellitus, typically type 2. Studies over the last decade have focused on the design and development of advanced oral delivery dosage forms using bio nano technologies and novel drug carrier systems. Such studies have demonstrated significantly enhanced delivery and safety of biguanides using nanocapsules. Enhanced delivery and safety have widened the potential applications of biguanides not only in diabetes but also in other disorders. Hence, this review aimed to explore biguanides’ pharmacokinetics, pharmacodynamics, and pharmaceutical applications in diabetes, as well as in other disorders.

Sign in / Sign up

Export Citation Format

Share Document